Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Vir Biotechnology, Inc. VIR

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$68.6M
▼ 7.6% YoY
$-438.0M
$-396.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

In oncology, we are advancing three Phase 1 clinical studies of dual-masked T-cell engagers (TCEs): VIR-5500 in patients with Prostate-Specific Membrane Antigen (PSMA)-expressing metastatic castration-resistant prostate cancer (mCRPC); VIR-5818 in patients with HER2-expressing tumors; and VIR-5525 in patients with EGFR-expressing tumors. As of December 31, 2025, we had 367 employees, 282 of whom were primarily engaged in research and development activities. Our employees who work full-time in the office are predominantly located in San Francisco, California and Bellinzona, Switzerland, and employees not within commuting distance of our office locations work remotely.

Written from the business description in Vir Biotechnology, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 23 February 2026. Every sentence was checked against that document before publication.

Growth

USD 68.6M
Revenue, FY2025 · full 9-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.1 · Net income -0.4
1.00B2.00B-0.25B-0.50B
2017202020232025
Compound annual growth
−65.1%
−2.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −2.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−639 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -699.2% · Net -638.9%
-1000%-2000%-3000%
201720212025
ROE
FY2025 · ROE -45.7%
20%40%-20%-40%
201720212025
Three returns, three denominators.
Gross margin100.0%
Operating margin-699.2%
Net margin-638.9%
EBITDAUSD -467.6M

Each USD of equity lost 46 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF -0.4
1.0B2.0B-0.3B-0.6B
201720212025

Total assetsUSD 1.0B
CashUSD 232.2M
Current ratio5.54×

Not available: we don't have the total debt figure for this period.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
VIR, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.10.10.11.61.10.10.00.00.0
Operating income $B−0.5−0.6−0.70.80.4−0.3−0.2−0.1−0.1
EBITDA $B−0.5−0.6−0.70.80.4−0.3−0.2−0.1−0.1
Income tax $B0.0−0.0−0.00.20.00.00.0−0.0−0.0
Net income $B−0.4−0.5−0.60.50.5−0.3−0.2−0.1−0.1
Free cash flow $B−0.4−0.5−0.81.6−0.1−0.2−0.1−0.1−0.1
EPS, diluted $−3.16−3.83−4.593.833.96−2.51−5.76−15.12−32.45
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %−45.7−38.1−33.529.449.2−52.4———
Shares out B0.140.140.130.130.130.130.110.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 34 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 12 checks were skipped: cost of revenue is not tagged before 2019. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image